| scholarly article | Q13442814 |
| P50 | author | Ralf Gold | Q99630149 |
| P2093 | author name string | Carsten Lukas | |
| Gisa Ellrichmann | |||
| Robert Hoepner | |||
| Barbara Bellenberg | |||
| Ruth Schneider | |||
| P2860 | cites work | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| Magnetic resonance spectroscopy - Revisiting the biochemical and molecular milieu of brain tumors | Q26751140 | ||
| Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab | Q26851341 | ||
| Neurological immune reconstitution inflammatory response: riding the tide of immune recovery | Q28082309 | ||
| Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry | Q28555138 | ||
| Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
| PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
| The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy | Q30689194 | ||
| Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making | Q30989929 | ||
| Proton magnetic resonance spectroscopy in multiple sclerosis | Q33390863 | ||
| Progressive multifocal leukoencephalopathy in HIV-1 infection | Q33506561 | ||
| Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). | Q33605681 | ||
| MR-visible lipids and the tumor microenvironment | Q33888362 | ||
| Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 | ||
| Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis | Q34089586 | ||
| Outcome and survival of asymptomatic PML in natalizumab-treated MS patients | Q34562841 | ||
| Asymptomatic reactivation of JC virus in patients treated with natalizumab | Q34801034 | ||
| Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
| Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations | Q35456727 | ||
| Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study | Q36135627 | ||
| Metabolic profile of PML lesions in patients with and without IRIS: an observational study | Q36198630 | ||
| Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 | ||
| Two-dimensional 1H NMR studies of membrane changes during the activation of primary T lymphocytes | Q36738203 | ||
| Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients | Q37206687 | ||
| Natalizumab: bench to bedside and beyond | Q38057927 | ||
| Progressive multifocal leukoencephalopathy therapy | Q38250227 | ||
| Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis | Q39303279 | ||
| Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy | Q39418067 | ||
| MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. | Q41361912 | ||
| Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis | Q43596641 | ||
| Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? | Q43897444 | ||
| Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis | Q44181544 | ||
| Computation of brain metabolite ratios in single-voxel proton MR spectroscopy: comparison between semiautomatic and automatic software. | Q45948717 | ||
| Choline and creatine are not reliable denominators for calculating metabolite ratios in acute ischemic stroke | Q46490296 | ||
| A case of natalizumab-associated progressive multifocal leukoencephalopathy-role for advanced MRI? | Q48108942 | ||
| Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy | Q48166332 | ||
| Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases | Q48414755 | ||
| Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy | Q48748890 | ||
| Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? | Q53132815 | ||
| Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T | Q71507291 | ||
| Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging | Q72114019 | ||
| Proton MR spectroscopy in a 1T open MR imaging system | Q82919422 | ||
| Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 | ||
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 454 | |
| P577 | publication date | 2017-09-05 | |
| P1433 | published in | Frontiers in Neurology | Q15817039 |
| P1476 | title | Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions | |
| P478 | volume | 8 |
Search more.